Lyell announces presentation of initial clinical data from the phase 1-2 clinical trial of impt-314 for the treatment of b-cell lymphoma at the 2024 american society of hematology (ash) annual meeting

South san francisco, calif., nov. 05, 2024 (globe newswire) -- lyell immunopharma, inc. (nasdaq: lyel), a clinical-stage company advancing a pipeline of next-generation car t-cell therapies for patients with solid tumors or hematologic malignancies, today announced that an abstract highlighting initial clinical data from the phase 1-2 study of impt-314 in large b-cell lymphoma will be presented by sarah m. larson, m.d., associate professor, department of medicine, medical director, immune effector cell therapy program, division of hematology/oncology, david geffen school of medicine at ucla, at the 66th american society of hematology (ash) annual meeting taking place in san diego, ca, december 7 – 10, 2024. impt-314 is a dual-targeting cd19/cd20 chimeric antigen receptor (car) t-cell product candidate being developed for patients with aggressive b-cell non-hodgkin's lymphoma.
ASH Ratings Summary
ASH Quant Ranking